JP2008535821A - 過剰に安定化したc−metを調節するための方法及び組成物 - Google Patents

過剰に安定化したc−metを調節するための方法及び組成物 Download PDF

Info

Publication number
JP2008535821A
JP2008535821A JP2008503236A JP2008503236A JP2008535821A JP 2008535821 A JP2008535821 A JP 2008535821A JP 2008503236 A JP2008503236 A JP 2008503236A JP 2008503236 A JP2008503236 A JP 2008503236A JP 2008535821 A JP2008535821 A JP 2008535821A
Authority
JP
Japan
Prior art keywords
met
antibody
antagonist
cell
stabilized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008503236A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008535821A5 (cg-RX-API-DMAC7.html
Inventor
モニカ コング−ベルトラン,
ダイネリ, エム. ウィックラマシンゲ,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37053941&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2008535821(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2008535821A publication Critical patent/JP2008535821A/ja
Publication of JP2008535821A5 publication Critical patent/JP2008535821A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2008503236A 2005-03-25 2006-03-24 過剰に安定化したc−metを調節するための方法及び組成物 Pending JP2008535821A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66548205P 2005-03-25 2005-03-25
PCT/US2006/010850 WO2006104911A2 (en) 2005-03-25 2006-03-24 Methods and compositions for modulating hyperstabilized c-met

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012116934A Division JP2012232979A (ja) 2005-03-25 2012-05-22 過剰に安定化したc−metを調節するための方法及び組成物

Publications (2)

Publication Number Publication Date
JP2008535821A true JP2008535821A (ja) 2008-09-04
JP2008535821A5 JP2008535821A5 (cg-RX-API-DMAC7.html) 2009-04-09

Family

ID=37053941

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008503236A Pending JP2008535821A (ja) 2005-03-25 2006-03-24 過剰に安定化したc−metを調節するための方法及び組成物
JP2012116934A Pending JP2012232979A (ja) 2005-03-25 2012-05-22 過剰に安定化したc−metを調節するための方法及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012116934A Pending JP2012232979A (ja) 2005-03-25 2012-05-22 過剰に安定化したc−metを調節するための方法及び組成物

Country Status (17)

Country Link
US (2) US7615529B2 (cg-RX-API-DMAC7.html)
EP (1) EP1868648B1 (cg-RX-API-DMAC7.html)
JP (2) JP2008535821A (cg-RX-API-DMAC7.html)
KR (1) KR20080000613A (cg-RX-API-DMAC7.html)
CN (1) CN101184506B (cg-RX-API-DMAC7.html)
AU (1) AU2006229989B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0611468A2 (cg-RX-API-DMAC7.html)
CA (1) CA2599988A1 (cg-RX-API-DMAC7.html)
ES (1) ES2539790T3 (cg-RX-API-DMAC7.html)
IL (1) IL185708A (cg-RX-API-DMAC7.html)
MX (1) MX2007011652A (cg-RX-API-DMAC7.html)
NO (1) NO20075412L (cg-RX-API-DMAC7.html)
NZ (1) NZ561211A (cg-RX-API-DMAC7.html)
RU (1) RU2404193C2 (cg-RX-API-DMAC7.html)
SG (1) SG159547A1 (cg-RX-API-DMAC7.html)
WO (1) WO2006104911A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200707953B (cg-RX-API-DMAC7.html)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7615529B2 (en) * 2005-03-25 2009-11-10 Genentech, Inc. Methods and compositions for modulating hyperstabilized c-met
SG188802A1 (en) * 2008-03-06 2013-04-30 Genentech Inc Combination therapy with c-met and egfr antagonists
KR101837053B1 (ko) * 2008-10-01 2018-03-12 암젠 리서치 (뮌헨) 게엠베하 종간 특이적 PSCAxCD3, CD19xCD3, c-METxCD3, 엔도시알린xCD3, EpCAMxCD3, IGF-1RxCD3 또는 FAPαxCD3 이중특이적 단일쇄 항체
PA8849001A1 (es) 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
CN102361884A (zh) * 2009-04-07 2012-02-22 罗氏格黎卡特股份公司 双特异性抗-ErbB-2/抗-c-Met抗体
CN102378768A (zh) * 2009-04-07 2012-03-14 罗氏格黎卡特股份公司 双特异性抗-ErbB-3/抗-c-Met抗体
NZ616382A (en) 2009-04-20 2015-04-24 Oxford Biotherapeutics Ltd Antibodies specific to cadherin-17
KR101671378B1 (ko) * 2009-10-30 2016-11-01 삼성전자 주식회사 c-Met에 특이적으로 결합하는 항체 및 그의 용도
KR101968766B1 (ko) 2009-11-05 2019-04-12 제넨테크, 인크. 이종 폴리펩티드의 분비를 위한 방법 및 조성물
EP3904391B1 (en) 2010-03-10 2024-07-10 Genmab A/S Monoclonal antibodies against c-met
CN103534268B (zh) * 2010-10-20 2016-05-18 牛津生物疗法有限公司 抗体
RU2013155695A (ru) 2011-06-30 2015-08-10 Дженентек, Инк. Препараты антител против с-мет
WO2013033008A2 (en) 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
EP2758430A4 (en) 2011-09-20 2015-06-03 Lilly Co Eli ANTI-C-MET ANTIBODY
WO2013049112A1 (en) * 2011-09-27 2013-04-04 Emory University Detection of biomarkers using magnetic resonance
KR20130036993A (ko) 2011-10-05 2013-04-15 삼성전자주식회사 c-Met의 SEMA 도메인 내의 에피토프에 특이적으로 결합하는 항체
SG11201402485UA (en) * 2011-11-21 2014-06-27 Genentech Inc Purification of anti-c-met antibodies
EP2708556B1 (en) 2012-09-12 2018-11-07 Samsung Electronics Co., Ltd Pharmaceutical composition for the use in a combination therapy for prevention or treatment of c-met or angiogenesis factor induced diseases
DK2839860T3 (da) 2012-10-12 2019-06-17 Medimmune Ltd Pyrrolobenzodiazepiner og konjugater deraf
US10260089B2 (en) 2012-10-29 2019-04-16 The Research Foundation Of The State University Of New York Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
EP2727941A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Method for the production of multispecific antibodies
WO2014067642A1 (en) 2012-11-05 2014-05-08 Mab Discovery Gmbh Method for the production of multispecific antibodies
SG11201506451UA (en) 2013-03-06 2015-09-29 Merrimack Pharmaceuticals Inc Anti-c-met tandem fc bispecific antibodies
ES2687439T3 (es) 2013-03-13 2018-10-25 Medimmune Limited Pirrolobenzodiazepinas y conjugados de las mismas
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
US9567641B2 (en) * 2013-07-03 2017-02-14 Samsung Electronics Co., Ltd. Combination therapy for the treatment of cancer using an anti-C-met antibody
WO2015073678A1 (en) 2013-11-14 2015-05-21 Endocyte, Inc. Compounds for positron emission tomography
SG11201607519VA (en) 2014-03-14 2016-10-28 Genentech Inc Methods and compositions for secretion of heterologous polypeptides
EP3122900A1 (en) 2014-03-24 2017-02-01 F. Hoffmann-La Roche AG Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
EP3193940A1 (en) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
MX378108B (es) 2014-09-16 2025-03-10 Servier Lab Anticuerpos anti-met y composiciones.
GB201419108D0 (en) * 2014-10-27 2014-12-10 Glythera Ltd Materials and methods relating to linkers for use in antibody drug conjugates
KR20170136536A (ko) 2015-03-16 2017-12-11 셀덱스 쎄라퓨틱스, 인크. 항-met 항체 및 그 사용 방법
MX2019002946A (es) 2016-09-14 2019-09-26 Abbvie Biotherapeutics Inc Anticuerpos anti-pd-1 y sus usos.
CN109862919A (zh) 2016-10-11 2019-06-07 免疫医疗有限公司 抗体-药物缀合物联合免疫介导的治疗剂
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗met抗體,結合met之雙特異性抗原結合分子及其使用方法
MX2020010813A (es) 2018-04-17 2021-01-08 Endocyte Inc Metodos de tratamiento de cancer.
CA3098103A1 (en) 2018-05-23 2019-11-28 Adc Therapeutics Sa Molecular adjuvant
CA3106403A1 (en) 2018-07-15 2020-01-23 Enochian BioPharma, Inc. Methods and compositions using recombinant dendritic cells for cancer therapy
MX2021010265A (es) 2019-02-26 2021-09-23 Janssen Biotech Inc Terapias de combinacion y estratificacion de pacientes con anticuerpos anti-egfr/c-met biespecificos.
MY208668A (en) 2019-05-14 2025-05-23 Janssen Biotech Inc Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors
US11850248B2 (en) 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
EP3972627A4 (en) 2019-05-20 2023-06-21 Endocyte, Inc. Methods for preparing psma conjugates
CN114340684B (zh) 2019-09-16 2025-09-12 瑞泽恩制药公司 用于免疫pet成像的放射性标记的met结合蛋白
BR112022015140A2 (pt) 2020-02-12 2022-10-11 Janssen Biotech Inc Tratamento de pacientes que têm mutações de salto do éxon 14 de c-met
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
CN114478788B (zh) 2020-11-11 2025-07-18 北京免疫方舟医药科技有限公司 一种同时靶向cd3和cd137的融合蛋白及其制备方法和用途
WO2022106629A1 (en) 2020-11-19 2022-05-27 Novartis Ag Synthesis of prostate specific membrane antigen (psma) ligands
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11506327A (ja) * 1995-06-02 1999-06-08 ジェネンテック インコーポレーテッド 肝細胞増殖因子受容体拮抗剤とその使用法
WO2005016382A1 (en) * 2003-08-04 2005-02-24 Pfizer Products Inc. Antibodies to c-met
WO2005063816A2 (en) * 2003-12-19 2005-07-14 Genentech, Inc. Monovalent antibody fragments useful as therapeutics

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE423852T1 (de) 1996-04-05 2009-03-15 Antonio Giordano Methoden zur diagnose und prognose von krebs
ATE465257T1 (de) * 1996-07-03 2010-05-15 Genentech Inc Agonisten für den rezeptor des hepatozyten- wachstumsfaktors und deren anwendungen
DE19651443A1 (de) * 1996-12-11 1998-06-18 Hoechst Ag Selbstverstärkende, pharmakologisch kontrollierbare Expressionssysteme
US20030228319A1 (en) * 2002-04-16 2003-12-11 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
MXPA05008521A (es) * 2003-02-13 2005-10-20 Pharmacia Corp Anticuerpos a c-met para el tratamiento de canceres.
WO2005001486A1 (en) * 2003-06-06 2005-01-06 Genentech, Inc. Modulating the interaction between hgf beta chain and c-met
CN1922208A (zh) * 2003-12-11 2007-02-28 健泰科生物技术公司 用于抑制c-met二聚化及活化的方法和组合物
US20060263808A1 (en) 2005-03-25 2006-11-23 Genentech, Inc. C-met mutations in lung cancer
US7615529B2 (en) 2005-03-25 2009-11-10 Genentech, Inc. Methods and compositions for modulating hyperstabilized c-met

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11506327A (ja) * 1995-06-02 1999-06-08 ジェネンテック インコーポレーテッド 肝細胞増殖因子受容体拮抗剤とその使用法
WO2005016382A1 (en) * 2003-08-04 2005-02-24 Pfizer Products Inc. Antibodies to c-met
WO2005063816A2 (en) * 2003-12-19 2005-07-14 Genentech, Inc. Monovalent antibody fragments useful as therapeutics

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JPN6011057761; Cancer Res., 65[4] (2005 Feb) p.1479-88. *
JPN6011057762; Gene, 215 (1998) p.159-169 *
JPN6011057763; Oncogene, Vol.9 No.7 (1994) p.2045-2052 *
JPN6011057764; J Biol Chem., Vol.269 No.30 (1994) p.19457-19461 *
JPN6011057765; Science, Vol.254 No.5036 (1991) p.1382-1385 *
JPN6011057766; Oncogene, Vol.19 No.49 (2000) p.5680-5689 *

Also Published As

Publication number Publication date
WO2006104911A3 (en) 2007-02-22
KR20080000613A (ko) 2008-01-02
RU2404193C2 (ru) 2010-11-20
US7615529B2 (en) 2009-11-10
WO2006104911A2 (en) 2006-10-05
NZ561211A (en) 2011-03-31
AU2006229989A1 (en) 2006-10-05
HK1109075A1 (en) 2008-05-30
CN101184506A (zh) 2008-05-21
CA2599988A1 (en) 2006-10-05
EP1868648A2 (en) 2007-12-26
US8536118B2 (en) 2013-09-17
ZA200707953B (en) 2009-06-24
MX2007011652A (es) 2007-11-14
CN101184506B (zh) 2013-07-17
AU2006229989B2 (en) 2012-02-02
IL185708A (en) 2014-11-30
JP2012232979A (ja) 2012-11-29
EP1868648B1 (en) 2015-04-15
BRPI0611468A2 (pt) 2010-09-08
US20060270594A1 (en) 2006-11-30
US20100028337A1 (en) 2010-02-04
IL185708A0 (en) 2008-01-06
ES2539790T3 (es) 2015-07-06
RU2007139452A (ru) 2009-04-27
SG159547A1 (en) 2010-03-30
NO20075412L (no) 2007-12-21

Similar Documents

Publication Publication Date Title
US7615529B2 (en) Methods and compositions for modulating hyperstabilized c-met
US12583937B2 (en) Compositions and methods for the diagnosis and treatment of tumor
JP5196654B2 (ja) 腫瘍の診断と治療のための組成物と方法
TW201142295A (en) Compositions and methods for the diagnosis and treatment of tumor
JP2013511993A5 (cg-RX-API-DMAC7.html)
JP2018512597A (ja) 突然変異体スムースンド及びその使用方法
US20130058960A1 (en) Compositions and methods for the diagnosis and treatment of tumor
JP2006512901A (ja) Achaete−Scute様−2ポリペプチドとそのコード化核酸並びに腫瘍の診断と治療のための方法
HK1109075B (en) Methods and compositions for modulating hyperstabilized c-met

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111122

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120209

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120523

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130205

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130301

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130308

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130405

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130412

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130716